340B Program. Issues related to drug pricing. General pharmaceutical issues. Pubic health issues. Issues related to MFN. Appropriations and budget legislation for FY27. Reconciliation. Issues related to supply chain and shortages. Issues on vaccine policy. PBM reform. FDA issues. IRA Implementation.
2026 · 3rd Quarter (July 1 - Sep 30)
MERCK & CO., INC.
Filed by TODD STRATEGY GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- TODD STRATEGY GROUP
- Client
- MERCK & CO., INC.
- Filing UUID
- c02d910b-f645-44d1-bbe4-011cfda8aa3d
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to Medicare Part B and D. Issues related to Medicaid Drug Rebate Program (MDRP).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.